Clinical Trials in China / NCT07230600
Recruiting
Phase 1
AD-SVF Therapy for Refractory Endometrial Infertility
NCT07230600 · tracked via the Priya Life Science China tracker
Condition(s) studied
Endometrium; AtrophyIntrauterine Synechiae
Investigational drug(s) / intervention(s)
AD-SVF
AD-SVF: AD-SVF is isolated and extracted from adipose tissue for intrauterine infusion therapy.
Study summary
The purpose of this study is to initially explore the efficacy of adipose-derived stromal vascular fraction (AD-SVF) therapy in the treatment of refractory endometrial infertility.
Eligibility
Inclusion Criteria:
1. refractory thin endometrium (endometrial thickness \< 6 mm on the day of ovulation or the day of endometrial transformation during a hormone replacement cycle) and/or moderate to severe intrauterine adhesion;
2. Inability to undergo autologous bone marrow stem cells-scaffold (BMSC) transplantation due to failed bone marrow aspiration, or lack of significant effect following the BMSC treatment;
3. with fertility intentions;
4. normal ovarian function or availability of cryopreserved embryos;
5. 18kg/m\^2 \< body mass index (BMI) \< 30kg/m\^2;
Exclusion Criteria:
1. Chromosomal karyotype abnormalities in one spouse;
2. Severe endometriosis, uterine fibroids affecting the uterine cavity morphology, or uterine malformations;
3. Abnormalities in coagulation function, hepatic or renal function, or other underlying conditions deemed by the investigator to potentially impact the study's progression (uncontrolled hypertension, diabetes, autoimmune diseases, etc.);
4. Contraindications for pregnancy;
5. Contraindications for hormonal cycle therapy;
6. History of pelvic tumors;
7. Simultaneous participation in other clinical studies.
Primary outcome measure(s)
- Proportion of patients with endometrial thickness of 6 mm or greater — 6 months after AD-SVF intrauterine infusion therapy
During the late proliferative phase, the endometrial thickness between anterior and posterior uterine walls is measured to be at least 6 mm through a median sagittal section of the uterus at least once.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Nanjing Drum Tower Hospital | Nanjing | Jiangsu | Recruiting |
More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China
Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy
Recruiting
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
Recruiting
CHT105 for the Treatment of Refractory Lupus Nephritis
Enrolling by invitation
Clinical Classification and Imaging Markers in Patients of Obesity
Enrolling by invitation
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07230600 on ClinicalTrials.gov ↗ ← All trials in China